Mechanism of Cediranib-Olaparib Combo Revealed.

abstract：:Tumors mutated in IDH1 tend to have lower levels of the essential substrate NAD+. In this issue of Cancer Discovery, Nagashima and colleagues exploit this metabolic sensitivity by devising a combinatorial therapy that both further reduces the pools as well as sequesters the remaining substrate in PAR chains, sensitizi...

journal_title：Cancer discovery

authors： Pirozzi CJ,Yan H

更新日期：2020-11-01 00:00:00

abstract：SUMMARY:In this issue of Cancer Discovery, Romero and colleagues identify somatic mutations and deletions of MAX, and also define what seem to be mutually exclusive alterations in MYC family members and other MYC-associated factors in small cell lung cancer. Taken together, these data highlight the importance of MYC si...

journal_title：Cancer discovery

authors： Rudin CM,Poirier JT

更新日期：2014-03-01 00:00:00

abstract：:Metastasizing tumor cells lose expression of the tumor suppressor PTEN at a much higher rate when they enter the brain compared to other organs, suggesting that the brain's unique microenvironment may prime metastatic cells for aggressive growth, a recent study reports. The findings may have implications for developin...

journal_title：Cancer discovery

authors：

更新日期：2016-01-01 00:00:00

abstract：:Amgen's novel small-molecule inhibitor AMG 510 has become the first drug to successfully target a KRAS mutation in patients, according to findings presented at the 2019 American Society of Clinical Oncology Annual Meeting. In a phase I trial, AMG 510 elicited partial responses in half of evaluable patients with KRASG1...

journal_title：Cancer discovery

authors：

更新日期：2019-08-01 00:00:00

abstract：:The IPRES signature is related to anti-PD-1 response, and high mutational load predicts survival. ...

journal_title：Cancer discovery

authors：

更新日期：2016-05-01 00:00:00

abstract：:In the large international phase III MAVORIC trial, patients with previously treated cutaneous T-cell lymphoma who received the anti-CCR4 monoclonal antibody mogamulizumab experienced significantly longer progression-free survival and higher response rates, as well as better quality of life, than those who received vo...

journal_title：Cancer discovery

authors：

更新日期：2018-02-01 00:00:00

abstract：:Preconditioning the immune system with a tetanus/diphtheria toxoid significantly improved the effectiveness of dendritic cell immunotherapy and extended overall survival in a small, randomized study of patients with glioblastoma. ...

journal_title：Cancer discovery

authors：

更新日期：2015-06-01 00:00:00

abstract：:Recent findings from a phase II trial suggest that combining the antiandrogen abiraterone and the PARP inhibitor olaparib significantly improves progression-free survival among patients with metastatic castration-resistant prostate cancer, regardless of their homologous recombination repair-mutation status. ...

journal_title：Cancer discovery

authors：

更新日期：2018-08-01 00:00:00

abstract：UNLABELLED:Although it is known that mTOR complex 2 (mTORC2) functions upstream of Akt, the role of this protein kinase complex in cancer is not well understood. Through an integrated analysis of cell lines, in vivo models, and clinical samples, we demonstrate that mTORC2 is frequently activated in glioblastoma (GBM), ...

journal_title：Cancer discovery

authors： Tanaka K,Babic I,Nathanson D,Akhavan D,Guo D,Gini B,Dang J,Zhu S,Yang H,De Jesus J,Amzajerdi AN,Zhang Y,Dibble CC,Dan H,Rinkenbaugh A,Yong WH,Vinters HV,Gera JF,Cavenee WK,Cloughesy TF,Manning BD,Baldwin AS,Mi

更新日期：2011-11-01 00:00:00

abstract：:IFNγ-producing NK cells induced TME remodeling and orchestrated T cell-mediated tumor control. ...

journal_title：Cancer discovery

authors：

更新日期：2020-12-04 00:00:00

abstract：:An expert panel recommended approval of Novartis's experimental chimeric antigen T-cell therapy, tisagenlecleucel, for children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia. The therapy would be the first of its kind approved for cancer and has the potential to transform standard of...

journal_title：Cancer discovery

authors：

更新日期：2017-09-01 00:00:00

abstract：:Internal tandem duplication of the FMS-like tyrosine kinase 3 gene (FLT3-ITD) occurs in 30% of poor prognosis acute myeloid leukaemias (AMLs). Limited clinical efficacy of FLT3 inhibitors highlights the need for alternative therapeutic modalities in this subset of disease. Using human and murine models of FLT3-ITD-dri...

journal_title：Cancer discovery

authors： Bjelosevic S,Gruber E,Newbold A,Shembrey C,Devlin JR,Hogg SJ,Kats L,Todorovski I,Fan Z,Abrehart TC,Pomilio G,Wei A,Gregory GP,Vervoort SJ,Brown KK,Johnstone RW

更新日期：2021-01-12 00:00:00

abstract：:Researchers have used mass spectrometry to conduct proteomic analyses of 77 genomically characterized breast tumors. Through this approach, they've uncovered functional consequences of somatic mutations. For instance, EGFR overexpression in basal-like breast cancer is potentially driven by the loss of two genes, SKP1 ...

journal_title：Cancer discovery

authors：

更新日期：2016-08-01 00:00:00

abstract：:CD30-directed CAR T cells were safe and produced a 62% overall response rate in Hodgkin lymphoma. ...

journal_title：Cancer discovery

authors：

更新日期：2020-09-01 00:00:00

abstract：UNLABELLED:Despite evidence implicating transcription factors, including STAT3, in oncogenesis, these proteins have been regarded as "undruggable." We developed a decoy targeting STAT3 and conducted a phase 0 trial. Expression levels of STAT3 target genes were decreased in head and neck cancers following injection with...

journal_title：Cancer discovery

authors： Sen M,Thomas SM,Kim S,Yeh JI,Ferris RL,Johnson JT,Duvvuri U,Lee J,Sahu N,Joyce S,Freilino ML,Shi H,Li C,Ly D,Rapireddy S,Etter JP,Li PK,Wang L,Chiosea S,Seethala RR,Gooding WE,Chen X,Kaminski N,Pandit K,Jo

更新日期：2012-08-01 00:00:00

abstract：:Protein-coding mutations in clear cell renal cell carcinoma (ccRCC) have been extensively characterized, frequently involving inactivation of the von Hippel-Lindau (VHL) tumor suppressor. Roles for noncoding cis-regulatory aberrations in ccRCC tumorigenesis, however, remain unclear. Analyzing 10 primary tumor/normal p...

journal_title：Cancer discovery

authors： Yao X,Tan J,Lim KJ,Koh J,Ooi WF,Li Z,Huang D,Xing M,Chan YS,Qu JZ,Tay ST,Wijaya G,Lam YN,Hong JH,Lee-Lim AP,Guan P,Ng MSW,He CZ,Lin JS,Nandi T,Qamra A,Xu C,Myint SS,Davies JOJ,Goh JY,Loh G,Tan BC,Roz

更新日期：2017-11-01 00:00:00

abstract：:LXR activation reduces immunosuppressive MDSCs to activate antitumor cytotoxic T cells. ...

journal_title：Cancer discovery

authors：

更新日期：2018-03-01 00:00:00

abstract：:The overall budget for the NCI has increased by about $1 billion since 2009, yet the payline for new R01 grants has continued to decrease, largely due to an influx of R01 grant applications. Researchers, troubled by this trend, are wondering why the NCI is receiving so many more applications and what can be done to im...

journal_title：Cancer discovery

authors：

更新日期：2019-05-01 00:00:00

abstract：:T cell-based therapies have induced cancer remissions, though most tumors ultimately progress, reflecting inherent or acquired resistance including antigen escape. Better understanding of how T cells eliminate tumors will help decipher resistance mechanisms. We used a CRISPR/Cas9 screen and identified a necessary role...

journal_title：Cancer discovery

authors： Upadhyay R,Boiarsky JA,Pantsulaia G,Svensson-Arvelund J,Lin MJ,Wroblewska A,Bhalla S,Scholler N,Bot A,Rossi JM,Sadek N,Parekh S,Laganà A,Baccarini A,Merad M,Brown BD,Brody JD

更新日期：2020-12-17 00:00:00

abstract：:53BP1 integrates pRB activity with the DNA damage response by binding to methylated K810. ...

journal_title：Cancer discovery

authors：

更新日期：2014-09-01 00:00:00

abstract：:Pancreatic ductal adenocarcinoma (PDAC) is the most lethal common malignancy, with little improvement in patient outcomes over the past decades. Recently, subtypes of pancreatic cancer with different prognoses have been elaborated; however, the inability to model these subtypes has precluded mechanistic investigation ...

journal_title：Cancer discovery

authors： Miyabayashi K,Baker LA,Deschênes A,Traub B,Caligiuri G,Plenker D,Alagesan B,Belleau P,Li S,Kendall J,Jang GH,Kawaguchi RK,Somerville TDD,Tiriac H,Hwang CI,Burkhart RA,Roberts NJ,Wood LD,Hruban RH,Gillis J,Krasnitz

更新日期：2020-10-01 00:00:00

abstract：:A phase III trial testing nivolumab to treat advanced melanoma was stopped early due to improved overall survival compared with standard chemotherapy. ...

journal_title：Cancer discovery

authors：

更新日期：2014-09-01 00:00:00

abstract：:A recent study integrating proteomic and genomic analyses uncovered unexpected similarities in some types of pediatric brain tumors, such as certain craniopharyngiomas and low-grade gliomas, suggesting potential treatments and more refined prognoses. ...

journal_title：Cancer discovery

authors：

更新日期：2021-01-07 00:00:00

abstract：:Metabolic reprogramming enables cancer cell growth, proliferation, and survival. This reprogramming is driven by the combined actions of oncogenic alterations in cancer cells and host cell factors acting on cancer cells in the tumor microenvironment. Cancer cell intrinsic mechanisms activate signal transduction compon...

journal_title：Cancer discovery

authors： Dey P,Kimmelman AC,DePinho RA

更新日期：2021-01-27 00:00:00

abstract：UNLABELLED:Pancreatic ductal adenocarcinoma is refractory to available therapies. We have previously shown that these tumors have elevated autophagy and that inhibition of autophagy leads to decreased tumor growth. Using an autochthonous model of pancreatic cancer driven by oncogenic Kras and the stochastic LOH of Trp5...

journal_title：Cancer discovery

authors： Yang A,Rajeshkumar NV,Wang X,Yabuuchi S,Alexander BM,Chu GC,Von Hoff DD,Maitra A,Kimmelman AC

更新日期：2014-08-01 00:00:00

abstract：:STAT3 palmitoylation increases dimerization, nuclear localization, and activation of target genes. ...

journal_title：Cancer discovery

authors：

更新日期：2019-09-06 00:00:00

abstract：:Hypoxia-inducible factors (HIF) have long been linked to malignant tumor phenotypes in various cancer types, and several downstream mediators of HIF action are deregulated in metastatic carcinomas. A new study links hypoxia-induced collagen remodeling to sarcoma progression, providing evidence for unifying mechanisms ...

journal_title：Cancer discovery

authors： Vanharanta S,Massagué J

更新日期：2013-10-01 00:00:00

abstract：:A phase II study indicates that sacituzumab govitecan (IMMU-132), a Trop-2-specific antibody linked to the irinotecan metabolite SN-38, prolongs the progression-free survival of patients with advanced triple-negative breast cancer. IMMU-132 is well tolerated, causing fewer and more manageable side effects than irinote...

journal_title：Cancer discovery

authors：

更新日期：2016-01-01 00:00:00

abstract：: In this study, McKeown and colleagues carried out a genome-wide characterization and stratification of the enhancer landscape in acute myeloid leukemia (AML). The authors' analysis led to the discovery of a novel RARA superenhancer found in a subset of patients with AML, rendering these leukemia cells highly sens...